又一“成都造”疫苗正式开启Ⅲ期临床试验

Core Viewpoint - Chengdu Maikang Biological Technology Co., Ltd. announced the completion of the first batch of subject enrollment for its self-developed recombinant respiratory syncytial virus vaccine (CHO cell) Phase III clinical trial in Xianning, Hubei Province, marking it as the first domestically developed RSV vaccine approved for clinical trials by the National Medical Products Administration [1] Group 1 - The vaccine is developed by a wholly-owned subsidiary of Chengdu Maikang Biological Technology [1] - This vaccine utilizes a recombinant protein technology route [1] - The clinical trial is significant as it represents a milestone in the domestic development of RSV vaccines in China [1]